BoBang Fangzhou: Jointly with Tsinghua University to develop non-invasive blood glucose meters, into the market of 10 billion.

Guide: Non-invasive blood glucose meter to open up the domestic first! According to the data released by the International Diabetes Alliance, in 2019, the number of people diagnosed with diabetes in China reached 116 million, plus 140 million people with prediabetes, the total number of people with diabetes has exceeded 260 million, making it the world's largest number of people with diabetes.
by 2030, China's diabetes population will reach 200 million, creating a huge diabetes market.
According to the "Digital Innovation Report on Diabetes Management" written by the Arterial Network Eggshell Research Institute, the diabetes market mainly includes the smart blood glucose meter market, the personalized service market, the oral sugar-lowering drug market and the insulin market, the potential size of the whole market will reach 134.9 billion yuan in 2025, of which the smart glucose meter market is about 18.4 billion yuan.
but at present, the market of blood glucose meters for fingertip blood, patients' compliance is lower, the use rate is low.
, is there a non-invasive product that accurately measures blood sugar? The answer is yes.
Bobang Fangzhou Medical Technology (Beijing) Co., Ltd. (Bobang Fangzhou) developed a non-invasive glucose meter can be non-invasive to estimate the concentration of glucose in adults, for healthy people and non-insulin treatment of type 2 diabetes patients in the family use, suitable for daily self-blood glucose management. Qiu Zan, chairman of
Bobang Fangzhou, said: "The non-invasive blood glucose meter products achieve completely non-invasive measurement, and do not use any consumables, reduce the risk of infection at the same time, so that the comprehensive cost of self-glycemic management can be reduced, for continuous testing of blood sugar to provide the possibility."
", Bobang Fangzhou, formerly known as Beijing Sanlian Yonghui Medical Technology Co., Ltd., was established in 2005, is a high-end medical equipment research and development, production and sales of China's national high-tech enterprises.
is understood that the non-invasive blood glucose meter project by Bobang Fangzhou and Tsinghua University in cooperation with the development, the project from research and development to clinical, accumulated tens of thousands of measurement data, its core technology has been a number of national invention patents.
found the point of fingertip blood pain, ten years of study of non-invasive blood glucose detection technology research in Tsinghua University from 2002, perfected the metabolic heat integration method theory system and algorithm, developed based on metabolic heat integration method non-invasive blood glucose detector.
the basic principle is: the body metabolism produced by the heat and blood sugar concentration, oxygen supply is positively related.
research team through temperature sensors, infrared sensors, humidity sensors, optical measuring devices and other monitoring equipment, will reflect the metabolic heat temperature, humidity, blood flow rate and blood oxygen saturation data, and then through the metabolic heat and blood glucose concentration, oxygen supply of the functional relationship to calculate, and finally get the blood glucose concentration value.
(measuring blood glucose flow, arterial network mapping) Qiu Zan introduced: "The non-invasive blood glucose meter project began in 2002 national 863 program 'whole blood multiparameter biochemical detection microsystem development project', the project concluded after Tsinghua University continued research, and in 2008 successfully developed a non-invasive blood glucose meter engineering prototype."
since then, Tsinghua University, in cooperation with Bobang Fangzhou, developed the first generation of products in 2013 and gradually productized scientific research results.
" the reason for choosing to product the non-invasive blood glucose meter, because Qiu Zan saw the fingertip blood test blood pain point: there is a way to measure blood sugar to reduce the patient's compliance, but also reduce the number of times the patient monitors blood sugar.
this leads to diabetes management difficulties, to patients and society has brought a great financial burden.
determined to engage in the field of blood glucose monitoring, Bobang Fangzhou after ten years, finally made the non-invasive blood glucose meter approved to market: in 2016, the first generation of products completed large sample clinical trials;
in the process, Bo BangFangzhou cooperated with medical institutions such as Peking University First Hospital, Peking University People's Hospital, Beijing Concord Hospital, Shanghai Sixth People's Hospital, Southeast University Affiliated University Hospital, Nanjing Gulou Hospital and other medical institutions to conduct clinical trials, and obtained the approval of the hospital and doctors.
it is worth mentioning that in 2018, Bobang Fangzhou was approved as a national high-tech enterprise, which also proves that its efforts have been recognized by the state and society.
compared to the available fingertip blood glucose measurement products on the market, Bobang Fangzhou non-invasive blood glucose meter uses multi-sensor integration technology to achieve non-invasive measurement of blood sugar in less than a minute.
the product uses finger-clamp-type operation, easy to operate, without worrying about the risk of infection caused by punctureskin.
at the same time, the patient's tolerance to the non-invasive glucose meter is good, can be tested multiple times a day, and the product will automatically store the measurement results, visualdisplay of blood glucose change trends.
this will effectively improve the efficiency of blood sugar management and promote fine blood sugar management.
in addition, the body of the non-invasive blood glucose meter is only seven inches, small in size, easy to carry, and a non-invasive blood glucose meter can be set up multiple users, no supplies can detect blood sugar, cost-effective.
(product wearing diagram, picture from the enterprise website) in terms of accuracy, after clinical trials, non-invasive blood glucose meter test results and intravenous blood test results compared to 94.5 percent, compared with fingertip blood test results, the consistency can reach 94.4%, with high accuracy.
noteworthy, because of the use of mathematical model algorithms, when the detection of the population increases, the detection data will be more accurate.
to fill the gaps in the field of domestic special medical devices, the second generation of non-invasive blood glucose meter is expected to be approved for the year listed non-invasive glucose meter project from research and development to registration of clinical, Tsinghua University lasted 17 years, Bobang Fangzhou after 10 years.
in the long-term research and development process, Bobang Fangzhou by virtue of the core technology to obtain four national invention patents, its technology leadership has been recognized by the relevant departments of the state, to fill the gap in the field of domestic and foreign special medical equipment.
at present, Bobang Fangzhou has developed a second generation of non-invasive blood glucose meter, and registration and approval work has entered the stage of replacement. "The second generation of non-invasive glucose meter products is expected to be approved this year, and start the market sales work,"
Qiu Zan revealed.
" in product promotion, Bobang Fangzhou plan to cooperate with high-quality product agents to promote product sales.
it is understood that Bobang Fangzhou has reached cooperation with domestic high-quality large agents, is expected to open the marketing work in the second half of the year.
in addition, Bobang Fangzhou adhere to the global layout, plans to take the domestic market as a starting point, and gradually to North America, Europe.
at present, Bo Bang Fangzhou is planning the FDA and CE declaration.
2019, Bobang Fangzhou obtained a medical device production license, but in response to large-volume orders, Bobang Fangzhou and Foxconn Group wholly-owned subsidiary also Zhuang Futai Jing Precision Electronics (Beijing) Co., Ltd. signed a commissioned production agreement, by which Bobang Fangzhou for raw materials inspection, production process control and production release.
is understood that BoBang Fangzhou is working with Foxconn to declare the Beijing Drug Administration medical device registrant system the first pilot.
on future planning, Bobang Fangzhou plans to develop non-invasive glucose meters into miniaturization and portability, while studying real-time continuous monitoring programs. "We will also expand the scope of detection through artificial intelligence technology to improve the accuracy of test results,"
.
," Qiu added.
at present, Bobang Fangzhou is carrying out a new round of financing, plans to raise 150 million to 200 million yuan, mainly used to broaden sales channels, increase investment in research and development, promote the speed of new products, at the same time, to prepare for overseas markets.
.